Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Terns Pharmaceuticals (TERN) Return on Capital Employed (2021 - 2025)

Terns Pharmaceuticals filings provide 5 years of Return on Capital Employed readings, the most recent being 14.78% for Q4 2025.

  • Quarterly Return on Capital Employed fell 1490.0% to 14.78% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 14.78% through Dec 2025, down 1490.0% year-over-year, with the annual reading at 2.96% for FY2025, 3093.0% up from the prior year.
  • Return on Capital Employed hit 14.78% in Q4 2025 for Terns Pharmaceuticals, down from 1.75% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.12% in Q4 2024 and bottomed at 41.97% in Q2 2024.
  • Average Return on Capital Employed over 5 years is 24.17%, with a median of 28.29% recorded in 2021.
  • The largest annual shift saw Return on Capital Employed plummeted -1587bps in 2024 before it surged 4118bps in 2025.
  • Terns Pharmaceuticals' Return on Capital Employed stood at 29.83% in 2021, then grew by 10bps to 26.81% in 2022, then decreased by -30bps to 34.85% in 2023, then skyrocketed by 100bps to 0.12% in 2024, then plummeted by -12699bps to 14.78% in 2025.
  • Per Business Quant, the three most recent readings for TERN's Return on Capital Employed are 14.78% (Q4 2025), 1.75% (Q3 2025), and 0.78% (Q2 2025).